Annals of Surgical Oncology

, Volume 24, Issue 4, pp 898–905 | Cite as

Management for Peritoneal Metastasis of Colonic Origin: Role of Cytoreductive Surgery and Perioperative Intraperitoneal Chemotherapy: A Single Institution’s Experience During Two Decades

  • Chukwuemeka IhemelanduEmail author
  • Paul H. Sugarbaker
Gastrointestinal Oncology



Peritoneal metastasis of colonic origin is associated with a poor prognosis. This study aimed to analyze the clinicopathologic characteristics and prognostic predictors of survival in a cohort of patients treated with cytoreductive surgery (CRS) and perioperative intraperitoneal chemotherapy (POIC) during two decades.


A retrospective study analyzed a prospectively maintained database for all patients treated for peritoneal metastasis of a colonic origin (PCC) from January 1990 to April 2015.


The 318 patients in our study comprised 171 men (53.8%) and 147 women (46.2%). The mean age of the patients at presentation was 50.6 years, (range 18–86 years). Overall survival was 42.5%, median survival and follow-up time was 21.5 and 15.0 months respectively. The 3 and 5 years survival rates were respectively 35 and 25%. The median survival time was 20.6 months for the men and 23.1 months for the women (p = 0.14). The mean intraoperative peritoneal carcinomatosis index (PCI) was 15.2. The patients who had a completeness of cytoreduction (CC) score of 0 or 1 (no residual disease <0.25 mm) had a median survival time of 36.6 months compared with 18.3 months for the patients with a CC-2 score and 7.6 months for the patients with a CC-3 score (p < 0.000). The significant independent predictors of survival in the multivariate analysis were the CC score and elevated tumor makers CA153 and CA125.


For patients with a limited extent of peritoneal metastases, CC is the most important prognostic variable for improved survival of colon cancer patients with peritoneal metastases.


Peritoneal Metastasis Cytoreductive Surgery Intraperitoneal Chemotherapy Peritoneal Cancer Index Complete Cytoreduction 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Howlader N, Noone AM, Krapcho M, et al (eds). SEER cancer statistics review, 19752010. National Cancer Institute, Bethesda 2013.Google Scholar
  2. 2.
    Minsky BD, Mies C, Rich TA, et al. Potentially curative surgery of colon cancer: patterns of failure and survival. J Clin Oncol. 1988;6:106–18.CrossRefPubMedGoogle Scholar
  3. 3.
    Russell AH, Tong D, Dawson LE, et al. Adenocarcinoma of the retroperitoneal ascending and descending colon: sites of initial dissemination and clinical patterns of recurrence following surgery alone. Int J Radiat Oncol Biol Phys. 1983;9:361–5.CrossRefPubMedGoogle Scholar
  4. 4.
    Jayne Fook DGS, Loi C, Seow-Choen F. Peritoneal carcinomatosis from colorectal cancer. Br J Surg. 2002;89:1545–50.CrossRefPubMedGoogle Scholar
  5. 5.
    Sadeghi B, Arvieux C, Glehen O, Beaujard AC, Rivoire M, Baulieux J, et al. Peritoneal carcinomatosis from non-gynecologic malignancies: results of the EVOCAPE 1 multicentric prospective study. Cancer. 2000;88:358–63.CrossRefPubMedGoogle Scholar
  6. 6.
    Loupakis F, Cremolini C, Masi G, Lonardi S, Zagonel V, Salvatore L, et al. Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer. N Engl J Med. 2014;371:1609–18.CrossRefPubMedGoogle Scholar
  7. 7.
    Pietrantonio F, Cremolini C, Petrelli F, Di Bartolomeo M, Loupakis F, Maggi C, et al. First-line anti-EGFR monoclonal antibodies in panRAS wild-type metastatic colorectal cancer: a systematic review and meta-analysis. Crit Rev Oncol Hematol. 2015;96,156–66.CrossRefPubMedGoogle Scholar
  8. 8.
    Franko J, Shi Q, Goldman CD, Pockage B, Nelson B, Goldberg R, et al. Treatment of colorectal peritoneal carcinomatosis with systemic chemotherapy: a pooled analysis of North Central Cancer Treatment Group phase III trials N9741 and N9841. J Clin Oncol. 2012;30:263–7.CrossRefPubMedGoogle Scholar
  9. 9.
    Klaver YL, Simkens LH, Lemmens VE, Koopman M, Teerenstra S, Bleichrodt RP, et al. Outcomes of colorectal cancer patients with peritoneal carcinomatosis treated with chemotherapy with and without targeted therapy. Eur J Surg Oncol. 2012;38, 617–23.CrossRefPubMedGoogle Scholar
  10. 10.
    Sugarbaker PH. An overview of peritonectomy, visceral resections, and perioperative chemotherapy for peritoneal surface malignancy. In: Sugarbaker PH (ed) Cytoreductive surgery & perioperative chemotherapy for peritoneal surface malignancy (textbook and video atlas). Cine-Med Publishing, Woodbury, CT, 2012, pp 1–30.Google Scholar
  11. 11.
    Sugarbaker PH. Dissection by electrocautery with a ball tip. J Surg Oncol. 1994;56:246–8.CrossRefPubMedGoogle Scholar
  12. 12.
    Jacquet P, Sugarbaker PH. Current methodologies for clinical assessment of patients with peritoneal metastasis. J Exp Clin Cancer Res. 1996;15:49–58.Google Scholar
  13. 13.
    Mohamed F, Sugarbaker PH. Intraperitoneal taxanes. Surg Oncol Clin North Am. 2003;12:825–33.CrossRefGoogle Scholar
  14. 14.
    Sugarbaker PH. An instrument to provide containment of intraoperative intraperitoneal chemotherapy with optimized distribution. J Surg Oncol. 2005;92:142–6.CrossRefPubMedGoogle Scholar
  15. 15.
    Elias D, Mariani A, Cloutier AS, Blot F, Goéré D, Dumont F, et al. Modified selection criteria for complete cytoreductive surgery plus HIPEC based on peritoneal cancer index and small bowel involvement for peritoneal carcinomatosis of colorectal origin. Eur J Surg Oncol. 2014a;40:1467–73.CrossRefPubMedGoogle Scholar
  16. 16.
    Benizri EI, Bernard JL, Rahili A, Benchimol D, Bereder JM. Small bowel involvement is a prognostic factor in colorectal carcinomatosis treated with complete cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy. World J Surg Oncol. 2012;10:56.CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Blackham AU, Russell GB, Stewart JH IV, Votanopoulos K, Levine EA, Shen P. Metastatic colorectal cancer: survival comparison of hepatic resection versus cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Ann Surg Oncol. 2014;21:2667–74.CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Yonemura Y, Canbay E, Ishibashi H. Prognostic factors of peritoneal metastases from colorectal cancer following cytoreductive surgery and perioperative chemotherapy. Sci World J. 2013;2013:978394.CrossRefGoogle Scholar
  19. 19.
    Elias D, Gilly F, Boutitie F, Quenet F, Bereder JM, Masvelt B, et al. Peritoneal colorectal carcinomatosis treated with surgery and perioperative intraperitoneal chemotherapy: retrospective analysis of 523 patients from a multicentric French study. J Clin Oncol. 2010;28:63–8.CrossRefPubMedGoogle Scholar
  20. 20.
    Froysnes I, Larsen S, Spasojevic M, et al. Complete cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for colorectal peritoneal metastasis in Norway: prognostic factors and oncologic outcome in a national patient cohort. J Surg Oncol. 2016. DOI: 10.1002/jso.24290.PubMedGoogle Scholar
  21. 21.
    Baratti D, Kusamura S, Pietrantonio F, et al. Progress in treatments for colorectal cancer peritoneal metastases during the years 2010–2015: a systematic review. Crit Rev Oncol Hematol. 2016;100:209–22.CrossRefPubMedGoogle Scholar
  22. 22.
    Faron M, Macovei R, Goere D, et al. Linear relationship of peritoneal cancer index and survival in patients with peritoneal metastases from colorectal cancer. Ann Surg Oncol. 2016;23:114–9.CrossRefPubMedGoogle Scholar

Copyright information

© Society of Surgical Oncology 2016

Authors and Affiliations

  1. 1.Program in Peritoneal Surface OncologyWashington Cancer InstituteWashingtonUSA

Personalised recommendations